8-K 1 tbuff_8k.htm CURRENT REPORT tbuff_8k.htm
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549
_____________

FORM 8-K
_____________

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 11, 2013
__________________________________________

Tribute Pharmaceuticals Canada Inc.
(Exact name of registrant as specified in its charter)
__________________________________________
 
Ontario, Canada
  
0-31198
  
Not Applicable
(State or other jurisdiction
  
(Commission File Number)
  
(I.R.S. Employer
of incorporation)
      
Identification Number)
 
151 Steeles Avenue East, Milton, Ontario, Canada
(Address of principal executive offices and zip code)
(519) 434-1540
(Registrant’s telephone number, including area code)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 
 
 
 
 
 
Item 7.01              Regulation FD Disclosure
 
On November 11, 2013, Tribute Pharmaceuticals Canada Inc. (the “Company”) issued a press release announcing Investigational New Drug Application for Bezalip® SR Cleared by the US Food and Drug Administration.  A copy of the Company’s press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
 
Item 9.01.             Financial Statements and Exhibits.
 
  (d)  
   Exhibits.
   
   99.1   Tribute Pharmaceuticals Canada Inc. Press Release, dated November 11, 2013.
 
 
 
2
 
 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
Tribute Pharmaceuticals Canada Inc.
  
       
Date: November 11, 2013
By:
/s/ Scott Langille
  
   
Name: Scott Langille 
  
   
Title Chief Financial Officer
  
       
 
 
 
 
 

3